Which set of effects is directly produced by mu receptor activation?
Choose an answer, then check it.
Clinical Pharmacology · Pain Management
Opioids
On this page 6 sections
In 30 seconds
Opioids relieve moderate-to-severe pain by activating opioid receptors, chiefly the mu receptor, in the brain and spinal cord. That same activation produces the euphoria, sedation, constipation, and respiratory depression that make opioids both effective and dangerous. Different opioids behave very differently — some are full agonists, some are partial or mixed agonist-antagonists, and several carry unique metabolic quirks that change how safely they can be used in a given patient. Safe opioid therapy depends less on which drug is chosen and more on matching the drug to the patient's organ function, genetics, and risk profile, then monitoring the right warning signs before harm occurs.
The college version
Receptors and What Mu Agonism Does
Opioid receptors are G-protein-coupled receptors found throughout the central and peripheral nervous system. The three classically taught are mu, kappa, and delta. Mu receptor activation drives nearly all clinically used opioid analgesics and produces a predictable cluster of effects: analgesia, euphoria (part of why opioids carry misuse potential), respiratory depression (the effect that kills in overdose), miosis (pinpoint pupils, a classic bedside clue), constipation (from slowed gut motility), and cough suppression (why some opioids are used as antitussives). Kappa activation contributes analgesia but tends toward dysphoria and sedation rather than euphoria. Delta receptors are less clinically targeted but modulate mood and analgesia. All these effects flowing from one receptor is the key to understanding why opioids both work and carry risk.
Classification
Full agonists — morphine, hydromorphone, oxycodone, hydrocodone, fentanyl, and methadone — fully activate the mu receptor with, in theory, no analgesic ceiling; effect increases with dose until side effects limit titration. These are the mainstay of moderate-to-severe pain management.
Partial agonists, such as buprenorphine, activate the mu receptor only partially, producing a ceiling on both analgesia and respiratory depression. This ceiling is part of why buprenorphine is used in opioid use disorder treatment — it satisfies receptors enough to prevent withdrawal without the same overdose risk as a full agonist.
Mixed agonist-antagonists, including butorphanol and nalbuphine, activate kappa receptors while blocking or weakly activating mu receptors. A critical safety point: giving one of these to a patient already receiving a full mu agonist can precipitate acute withdrawal by displacing the full agonist from the receptor.
Pure antagonists, such as naloxone, occupy the receptor without activating it, reversing agonist effects. This class is covered in depth in the companion topic on opioid overdose.
Special Properties to Know
Several opioids have quirks that change clinical decision-making. Morphine converts to an active metabolite cleared renally; in renal impairment this metabolite accumulates, causing prolonged sedation and respiratory depression even when the parent drug dose seems appropriate. Codeine and tramadol are prodrugs requiring conversion by liver enzyme CYP2D6 into their active forms; ultrarapid metabolizers convert them unusually fast and can experience dangerous, unpredictable toxicity, while poor metabolizers get little relief at all. Methadone has a long, highly variable half-life that outlasts its shorter analgesic duration, risking accumulation and delayed-onset respiratory depression with repeated dosing; it also prolongs the QT interval, raising arrhythmia risk, so periodic ECG monitoring is often warranted. Fentanyl is extremely potent and available as a transdermal patch; patch absorption increases with heat (fever, heating pads, hot showers, saunas), which can push a stable patient toward overdose, so patients must avoid direct heat over patches. Meperidine produces a neurotoxic metabolite that accumulates with repeated dosing or renal impairment, causing tremor, agitation, and seizures — why it has fallen out of favor beyond very short-term use.
Routes, Formulations, and PCA
Opioids are given orally, intravenously, intramuscularly, transdermally, and via patient-controlled analgesia (PCA) pumps that let patients self-administer small intravenous doses within programmed safety limits. The foundational safety rule is that only the patient may press the PCA button — anyone else pressing it removes the built-in safeguard, because a patient becoming too sedated to press the button naturally stops dosing before overdose occurs.
Adverse Effects and Monitoring
Tolerance develops to most side effects — sedation, nausea, respiratory depression — over days to weeks, but constipation does not develop tolerance and persists for as long as the drug is used. Every patient on scheduled opioids should start a proactive, scheduled bowel regimen rather than waiting for constipation to occur. The single most important monitoring principle is that increasing sedation precedes respiratory depression; a patient becoming difficult to arouse is showing the warning sign before breathing slows dangerously, so sedation level, not just respiratory rate, must be assessed regularly.
Tolerance, Dependence, and Opioid Use Disorder
These three concepts are distinct and should never be conflated. Tolerance is a physiologic need for higher doses to achieve the same effect. Physical dependence is the body's adaptation such that stopping abruptly causes withdrawal; both are expected, normal responses in anyone taking opioids regularly, including patients using them exactly as prescribed. Opioid use disorder is a separate, diagnosable condition involving compulsive use despite harm and loss of control. Conflating dependence with addiction stigmatizes patients who need ongoing pain control and can lead to undertreated pain.
Equianalgesic Conversion and Multimodal Care
Because opioids differ enormously in potency, converting a patient from one opioid or route to another requires equianalgesic principles rather than a one-to-one dose swap; incomplete cross-tolerance means a patient tolerant to one opioid is often not fully tolerant to an equivalent calculated dose of a different opioid, so conversions typically start at a reduced dose and titrate to effect. Multimodal analgesia — combining opioids with non-opioid agents, regional techniques, and non-pharmacologic strategies — allows lower opioid doses while maintaining control, reducing side-effect burden and misuse risk; this opioid-sparing approach is now standard practice.
Safety, Storage, and Disposal
Unused opioids should be stored securely, away from household members including children and adolescents, and disposed of promptly through take-back programs rather than kept indefinitely. Co-prescribing naloxone is increasingly standard for patients on chronic opioid therapy or at elevated overdose risk; naloxone's mechanism and use are detailed in the companion overdose topic.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of your brain as having special locks called opioid receptors, and opioid medicines are shaped like keys that fit those locks. When the key turns the lock, it turns off pain messages — but it also does other things at once, like a master switch controlling several lights. Turning it makes pain go away, but it also makes you sleepy, shrinks your pupils, slows your gut, and can slow your breathing if turned too hard.
Not every key turns the lock all the way. Some medicines, like morphine, turn it all the way (full agonists). Some, like buprenorphine, only turn it partway, so it's gentler and safer even at higher amounts. Some medicines jam the lock in a strange way instead of turning it smoothly.
Some of these keys have special quirks too. One gets stuck in your body longer if your kidneys aren't working well. Two only "turn on" after your liver changes their shape, and some people's livers do that so fast it becomes dangerous. One stays in your body a long, unpredictable time and can mess with your heartbeat. One comes as a sticky patch, and heat — like a hot bath — makes the patch dump medicine into your body faster than it should.
The gut-slowing effect never goes away, even after weeks of use, so doctors give a stool softener from day one instead of waiting for a problem. And the most important safety rule: people get sleepy first, before breathing gets slow — so nurses watch how easily you wake up, not just your breathing, to catch trouble early.
Also, needing more medicine over time or feeling sick when you stop isn't the same as being "addicted" — that's your body adjusting, like getting used to a strong flavor. Addiction is a separate problem where someone loses control over using a drug even though it's hurting them.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A nurse finds a hospitalized patient's spouse pressing the PCA button because the patient is "too tired to do it." What is wrong with this, and what should the nurse do?
Show answer
Only the patient should press their own PCA button, because the design relies on the patient becoming too sedated to keep pressing it as a built-in overdose safeguard; the nurse should stop the spouse, explain the safety reasoning, and reassess the patient's pain control and sedation level directly.
The whole safety idea behind PCA is that if you get too sleepy, you naturally stop pressing the button before you get more medicine than is safe. If someone else presses it for you, that built-in stop sign disappears, and you could get an unsafe amount while too drowsy to say so.
A patient has been on a stable oral opioid regimen for two months and needs a bowel regimen adjustment, while a colleague comments the patient is "getting addicted" because the dose has increased. How would you explain the difference between what is actually happening and opioid use disorder?
Show answer
Needing a higher dose over months of legitimate use reflects tolerance and physical dependence, which are expected, normal body adaptations to regular opioid exposure and are not the same as opioid use disorder, which involves compulsive use and loss of control despite harm.
Getting used to a medicine and needing more for the same effect is just how bodies work, similar to needing louder music over time to notice it as loud. It doesn't mean someone is addicted — addiction is a different struggle where a person can't control their use even when it's hurting them, and calling ordinary tolerance "addiction" can unfairly make people afraid to get the pain relief they actually need.
Quick check
3 questions here. Answers stay hidden until you check.
A patient stable on a fentanyl patch develops a high fever and takes a hot bath. What is the most immediate concern?
Choose an answer, then check it.
Which statement about mixing opioid classes is correct?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.